We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Likely to Refuse Intarcia’s Exenatide Combination Product
FDA Likely to Refuse Intarcia’s Exenatide Combination Product
The FDA said it was proposing to refuse Intarcia Therapeutics’ drug-device combination product, ITCA 650, for continuous release of the type II diabetes drug exanatide.
To View This Article:
Login
Subscribe To International Devices & Diagnostics Monitor